Late Breaking Clinical trials
Monday, April 15th, 08:30 - 10:10, Room 7/8
Access the free live streaming of the Late Breaking Clinical Trials session
ISN takes its commitment to dissemination of new knowledge seriously and, as such, streamed live “Late Breaking Clinical Trials” from the WCN. The purpose of this session was to give the worldwide nephrology community in-depth understanding of the rationale, execution and results of these 3 major nephrology studies: CREDENCE, SONAR and ACTIVE
The Late Breaking Clinical Trials session was streamed live from WCN 2019 on April 15, 2019 at 08:30 am
Watch the recording here
About the Late Breaking Clinical Trials
Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Clinical Trial
The CREDENCE trial, a comparative study of the efficacy and safety of canagliflozin versus placebo, has been concluded on the basis of a planned interim data analysis. CREDENCE was a randomized, double-blind, placebo controlled study involving multiple clinical centers. It enrolled about 4400 patients with T2D, with estimated glomerular filtration rate (eFGR) ≥30 to <90 mL/min/1.73 m2, and albuminuria.
The Study Of diabetic Nephropathy with AtRasentan (SONAR) trial
The SONAR trial is a randomized double blind, placebo controlled study comparing the efficacy and safety of the selective endothelin antagonist atrasentan with placebo in patients with type 2 diabetes and chronic kidney disease. This drug class is known for its potent albuminuria lowering capacity.
THE ACTIVE (A Clinical Trial of IntensiVE) Dialysis study
Quotidian hemodialysis appears to have clinical benefits, but whether it reduces mortality is unclear. The long term follow up analyses of the FHN randomised studies suggested a significant mortality benefit for frequent dialysis but possible harm for nocturnal dialysis. The ACTIVE Dialysis team will present pre-specified randomised analyses of the impact of extended hours hemodialysis on mortality during the interventional period and subsequent 4 year observational follow-up.
